
Prescription of cardiovascular medication in children with congenital heart defects across six European Regions from 2000-2014: Data from the EUROlinkCAT population based cohort study

Mads Damkjær1, Stine Kjaer Urhoj1,2, Joachim Tan3, Gillian Briggs3, Maria Loane4, Joanne Given4, Laia Barrachina-Bonet5, Clara Cavero-Carbonell5, Alessio Coi6, Amanda J Neville7, Anna Heino8, Sonja Kiuru-Kuhlefelt8, Sue Jordan9, Ieuan Scanlon9, Anna Pierini6,10, Aurora Puccini11, Ester Garne1, and Joan K Morris3

1 Department of Paediatrics, Lillebaelt Hospital – University Hospital of Southern Denmark, 6000, Kolding, Denmark

2 Section of Epidemiology, Department of Public Health, University of Copenhagen, Copenhagen, Denmark

3 Population Health Research Institute, St George’s, University of London, London, UK

4 Faculty of Life & Health Sciences, Ulster University, Northern Ireland, United Kingdom

5 Rare Diseases Research Unit, Foundation for the Promotion of Health and Biomedical Research in the Valencian region, Valencia, Spain

6 Unit of Epidemiology of Rare Diseases and Congenital Anomalies, Institute of Clinical Physiology, National Research Council, Pisa, Italy

7 Registro IMER - IMER Registry  (Emila Romagna Registry of Birth Defects), Center for Clinical and Epidemiological Research, University of Ferrara, Azienda Ospedaliero- Universitaria di Ferrara. Corso Giovecca, 203. 44121 Ferrara (Italy)

8 THL National Institute for Health and Welfare, Information Services Department, Helsinki, Finland

9 Faculty of Health & Life Science | Cyfadran Gwyddorau Bywyd ac Iechyd,  Swansea University | Prifysgol Abertawe

10 Fondazione Toscana Gabriele Monasterio, Pisa, Italy

11 Territorial Assistance Service – Drug and Medical Device Area, Emilia Romagna Health Department, Bologna, Italy

Short title: Prescription in congenital heart defects

*Key words*: congenital anomalies, congenital heart defects, cardiovascular medication, paediatric cardiology, child health

Article word count: 4114

Figures: 2

Tables: 3

**Author for correspondence:** Mads Damkjær, MD, PhD

Department of Paediatrics, Lillebaelt Hospital – University Hospital of Southern Denmark, Skovvangen 4-8, DK-6000, Kolding, Denmark.

Email: mads.damkjaer2@rsyd.dk

**Abstract**

*Objectives*: Advances in surgical management strategies have substantially reduced fatality from congenital heart defects (CHD). Decreased infant mortality might be expected, consequentially to result in greater morbidity in older children due to complications later in childhood and adolescence. This study aims to evaluate the use of cardiovascular medication (CVM) as an indicator of disease burden in children born with CHD in the first 10 years of life.

*Design*: Population-based cohort study.

*Setting*: Six population-based registries from the European Surveillance of Congenital Anomalies (EUROCAT) network participated. Data from live born children with major congenital anomalies (CA) born from 2000 - 2014 were linked to prescription databases. Four groups of children were analysed: CA, CHD, severe CHD (sCHD) and Ventricular Septal Defect (VSD) without sCHD. Live born children without CA were included as reference group.

*Participants*: We obtained data on 61,038 children born with a CA, including 19,678 with CHD, 3,392 with sCHD, 12,728 children with VSD without sCHD, and 1,725,496 reference children.

*Results*: Children born with sCHD were the most likely to receive a CVM prescription (42.9%, 95% CI, 26.3-58.5) in the first year of life compared to 13.3% (6.7-22.0) of children with any CHD, 5.9% (3.7-8.7) of children with any CA and 0.1% (0.0-0.1) of reference children. Medication was less likely to be prescribed after the first year of life for sCHD; 18.8% (14.8-23.1) for children 1-4 years and 15.8% (12.0-20.1) 5-9 years. Children with sCHD were most likely to receive a diuretic (36.4%, 18.6-54.5), an antihypertensive (6.9%, 3.7-11.3) or a beta-blocker (5.5%, 2.9-9.2).

*Conclusion*: Almost half of all children with sCHD were prescribed CVM in their first year of life. For all four groups of children with anomalies, the proportion of children with a CVM prescription decreased with age.

**Strengths and limitations of this study**

* That this is a population-based study covering all children and not only those referred to tertiary hospitals for treatment.
* The study spans a 15-year period and covers six different European regions, and are thus able to include data on more than 1.7 million children.
* The use of reference children for comparison enables interpretation of the results for children with congenital anomalies in the context of results for unaffected children.
* A limitation of this study is the lack of information about hospital prescribed medication. As a consequence, the exposure to CVM will be underestimated in this study.

**Introduction**

Congenital anomalies (CA) span a wide spectrum of diseases; from minor anomalies with minimal clinical significance, to severe malformations incompatible with life. It has been estimated that CA account for 1% of all deaths worldwide, ranking as the 23rd most prevalent cause of death for all age groups1. As children with CA tend to die within the first year of life, the burden in terms of years of life lost is high – and from this perspective CA are ranked 14th among the causes of death. As an example of this, CA were associated with about 40% of all infant deaths in Sweden and England from 2003 to 20122. Advances in surgical management strategies and pharmacological treatment have substantially reduced fatality and as such, the proportion of children born with a CA surviving beyond infancy is increasing3. This is the case not only for CA in general, but also for specific subgroups such as congenital heart defects (CHD) which account for one third of all CAs. Decreased infant mortality might be expected, consequentially to result in greater morbidity in older children due to complications later in childhood and adolescence.

Multiple studies have shown that a significant proportion of children with CHD have a decreased quality of life4. One factor that has been shown to negatively affect both the child’s and mother’s quality of life is taking daily medication, the effect of which appears independent of self-reported physical performance5. Similarly, among adults operated for coarctation of the aorta in childhood, their self-reported quality of life was significantly lower if they were receiving medication compared to age matched controls with similar exercise capacity who were likewise operated in childhood6. To our knowledge, it is not well understood, why medication has a negative impact on quality of life. It is tempting to speculate, that having to remember to take medication is a daily reminder of the disease and may trap patients in a vicious cycle of anxiety. In this context, it is notable that prescription of cardiovascular medication (CVM) to children in both Denmark and Norway has increased in the last 18 years – whilst the prevalence of CHD has remained constant7. Despite this finding some authors have argued that there has been a state of nihilism in prescription of CVM to children with chronic heart failure so that medications known to be effective in adults are withheld from children8. As pointed out in the European Society of Cardiology (ESC) guidelines on management of Adults with CHD: “The few available data on heart failure treatments (…) are often not conclusive and derived from small patient cohorts. As a consequence (…) recommendations are mostly based on clinical experience or position statements.”9, this is a problem that is even more pertinent for children with CHD. We have previously argued that with the paucity of data on both clinical effect of medication, which medication are being prescribed and to whom, it is “difficult to argue a case of either under- or over-treatment”7.

The aim of the EUROlinkCAT10 project is to investigate the survival, morbidity and educational outcomes of children with specific CA for the first 10 years of their lives by linking births with CA in EUROCAT registries to electronic health care and education databases. The European network of population-based registries for the epidemiological surveillance of congenital anomalies (EUROCAT) started in 1979 and now includes 39 registries in 21 countries covering more than 29% of births in Europe11. In this paper, using data from 6 European regions covering a period of 15 years, we examine prescription of CVM (i.e., antiarrhythmics, antihypertensives and diuretics) in the first ten years of life for children with CA overall and for children with CHD, including Severe Congenital Heart Defects (sCHD) and Ventricular Septal Defect (VSD) without sCHD, compared to a cohort of reference children without CA.

**Methods**

*Study design*: The study is a European, population-based linkage cohort study based on data from the European network of population-based registries for the epidemiological surveillance of congenital anomalies EUROCAT)12 linked with local prescription databases. As previously described in detail13, thirteen population-based registries from the EUROCAT network planned to participate in this linkage study. Live born children with a major CA recorded in the EUROCAT registry born between 2000 (or the first year of the EUROCAT registry if later) and 2014 were included. Live born children without CA born during the same time-period and from the same population area covered by the registry were included as a reference group.

Information on prescriptions up to ten years of age for all children were available by linking to local prescription databases. Data on medications were included from the year 2000 or the first birth year included in the study by each registry up to the end of 2015. Wales had information on prescriptions issued by the general practitioner (GP) for approximately 70% of Welsh GP practices that were part of the Secure Anonymised Information Linkage (SAIL) databank during the study period. The other five registries had information on prescriptions prescribed by a hospital doctor/ GP that were dispensed by a pharmacy in their region. No registry had information on hospital inpatient prescribing. All registries used ATC coding except for Wales. Wales used READ coding which was converted to ATC coding using a look-up table in SAIL. Details of the prescription databases are shown in Table 1. A study protocol was developed for EUROCAT registries to obtain local ethical approval for the linkage. The process of obtaining permissions for the study took longer than the six months expected when the study was planned, and eventually five registries could not contribute to the prescription study due to the difficulties in getting the approval. One registry did not have information on 7-digit Anatomical Therapeutical Chemical (ATC) codes and was excluded from this part of the prescription studies and one registry withdrew from the EUROlinkCAT study due to Covid19 response obligations. In total, data from six registries covering a population of more than 22 million people from five countries were included.

*Time period of study***:** It was decided to restrict the study period to 3 time periods (2000-2004, 2005-2009, and 2010-2014). Only Denmark; Funen, Finland and Wales had prescription data from 2000.

*Minimum number of prescriptions:* For CVM, a child must have had at least one prescription to be classified as exposed to CVM.

## *Small numbers*: Two registries (Denmark; Funen and Wales) have rules for releasing data with small numbers from their databases. In both registries, numbers less than 5 are not allowed. The rule also applies if the small number can be calculated from other numbers in the data tables. The SAIL databank (Wales) provided data to the EUROlinkCAT Central Results Repository (CRR) based at Ulster University with the requirement that any individual results involving fewer than five people were not released.

*Definitions of anomalie*s: Children with the below listed diagnoses were included in the study and divided into four groups according to the EUROCAT definitions14:

*CA*: All Q-codes in the ICD-10 diagnosis system (Finland and Italy used ICD-9 codes for part of the study period, only the ICD-10 codes are listed here), excluding minor anomalies according to EUROCAT exclusion criteria15. Finland and Italy used ICD-9 codes for part of the study period and therefore the equivalent ICD9 codes were included and excluded.

*CHD*: diagnosis Q20–Q26, excluding patent ductus arteriosus (PDA) (Q25.0) and peripheral pulmonary branch stenosis (Q25.6) if gestational age <37 weeks and persistent foramen ovale (Q21.11) for all gestational age groups.

*Severe CHD*: all diagnoses of common arterial truncus (Q20.0), transposition of great vessels (Q20.3), single ventricle (Q20.4), atrioventricular septal defect (Q21.2), Tetralogy of Fallot (Q21.3), pulmonary valve atresia (Q22.0), tricuspid atresia or stenosis (Q22.4), Ebstein’s anomaly (Q22.5), hypoplastic right heart (Q22.6), aortic valve atresia or stenosis (Q23.0), hypoplastic left heart (Q23.4), coarctation of the aorta (Q25.1), and total anomalous pulmonary vein return (Q26.2). These CHD were classified as severe according to their perinatal mortality rate16.

*VSD, excluding severe CHD*: all types of VSD either isolated or associated with other CHD diagnosis, but excluding sCHD. The aim with this category was to provide an estimate for milder cases of CHD.

*Classification of medication*: Prescription databases categorize medication according to the WHO based ATC classification, whereas clinical guidelines on prescription of antiarrhythmic medication from both the ESC and American Heart Association (AHA) are based on the Vaughan Williams classification (VWC)17. We have chosen to classify antiarrhythmic medication according to the VWC (for comparison of the two systems refer to Box 1). Antihypertensive medication and diuretics were classified according to the ATC system. In brief, this gave us the classification outlined below:

* VWC1: ATC codes C01BA (excluding C01BA51 and C01BA71), C01BB and C01BC,
* VWC2: ATC codes C07A
* VWC3: ATC codes C01BD
* VWC5: ATC codes C01AA05
* Antihypertensives: ATC codes C08 and C09
* Diuretics: ATC codes C03

Calcium antagonists were grouped with antihypertensives due to small numbers.

*Statistical methods*: We estimated the proportion of children receiving a prescription within three age groups (<1 year, 1-4 years, 5-9 years) using Kaplan-Meier survival estimates to account for the censoring occurring especially in the older age groups. Three registries had no information on children over 6 years of age, as their prescription data started in 2008 (Italy: Emilia Romagna and Tuscany) and 2010 (Spain: Valencian region), and so they were excluded from the 5-9 years’ analysis. The confidence intervals for the KM survival analysis estimates were calculated by STATA (version 16) using the ln(-ln(S(t))) transformation. To obtain pooled estimates of these proportions across registries random effects inverse-variance meta-analyses were performed using the ln(-ln(S(t))) transformation. For some anomaly groups and medications no children received a prescription and the Kaplan Meier survival analysis did not provide estimates of the confidence interval. Here, the upper confidence interval was calculated using the exact binomial estimates with the number of children at the start of the age category as the denominator, the proportion of children with a prescription was estimated to be 0.1% and the lower 95% confidence interval was calculated assuming symmetry on the ln(-ln(S(t)) scale.ADDTO METHODS HERE

*Patient public involvement*: The EUROlinkCAT project focusses on the lives of children with CAs in Europe during their first ten years of life. As part of the project we have plans for dissemination and knowledge exchange with parents as described in detail on our webpage18.

**Results**

*Population characteristics*: We obtained data from six EUROCAT registries spanning 15 birth years from 2000-2014. The reference population comprised 1,725,496 children without CA. In total 61,038 children with CA were included, of whom 19,678 had a CHD, including 3,392 with sCHD and 12,728 with a VSD without sCHD (Table 1). The percentage of children with valid identifications that could be linked to the prescription databases range from 85% (UK: Wales), 88% (Italy: Tuscany), 95% (Italy: Emilia-Romagna) to 100% (Spain: Valencia; Denmark: Funen; Finland).

*Proportion of children with a prescription according to anomaly*: The percentage of children with a CVM prescription correlated with severity of anomaly across all three age groups (Table 2, Fig. 1). The percentage of children <1 year old receiving any CVM prescription was 0.1% (95% CI, 0.0 – 0.1) for reference children, 5.9% (95% CI, 3.7 – 8.7) for any CA, 13.3% (95% CI, 6.7 – 22.0) for children with CHD, 42.9% (95% CI, 26.3 – 58.5) for children with sCHD and 7.4% (95% CI, 3.5 – 13.2) for children with VSD without sCHD. Prescription rates correlated with severity of anomaly across all three age groups (Table 2, Fig. 1). The same pattern of prescription was observed across all six European Regions, with no significant differences in overall prescription between regions.

*Proportion of children with a prescription according to age:* For the reference children there was no significant changes with age (from 0.1%, (95% CI, 0.0 – 0.1) to 0.2%, (95% CI, 0.0 – 0.2) across the three age groups). Among children with any CA, prescription was highest in the first year of life (5.9%, 95% CI, 3.7 – 8.7), and lower in the ensuing years with 3.1% (95% CI, 2.8 – 3.4) for ages 1 – 4 years and 2.3% (95% CI, 1.9 – 2.7) for ages 5 – 9 years. In CHD it was 13.3% (95% CI, 6.7 – 22.0) for children < 1 years, 5.9% (95% CI, 4.4 – 7.6) for ages 1 – 4 years and 3.7% (95% CI, 2.6 – 5.1) for ages 5 – 9 years. The same pattern with highest prescription in the first year of life and then declining prescription rates with age occurred in sCHD; 42.9% (95% CI, 26.3 – 58.5) in the first year, 18.8% (95% CI, 14.8 – 23.1) for ages 1 - 4 years and 15.8% (95% CI, 12.0 – 20.1) for ages 5 – 9 years (Table 1, Fig. 1). For children born with a VSD without sCHD, the highest prescription rates were in the first year of life (7.4%, 95% CI, 3.5 – 13.2) and 2.6% (95% CI, 1.7 – 3.9) for 1 – 4 years and 0.9% (95% CI, 0.7 – 1.2) for 4 – 9 years (Table 1).

*Choice of medication classes in sCHD*: Diuretics were the most frequently prescribed CVM in all three age groups, with 36.4% (95% CI, 18.6 – 54.5) in the first year of life, 14.1% (95% CI, 10.8 – 17.8) for ages 1 – 4 years and 8.5% (95% CI, 7.1 – 10.1) for ages 5 – 9 years. Listed in order of decreasing frequency of children receiving at least one prescription in their first year of life we found: antihypertensives 6.9% (95% CI, 3.7 – 11.3), VWC2 5.5% (95% CI, 2.9 – 9.2), VWC5 3.2% (95% CI, 1.1 – 7.0), VWC1 0.3 (95% CI, 0.0 – 1.2) and VWC3 0.2% (95% CI, 0.1 – 0.6). The same trends occurred for the two groups of older children, albeit with lower proportions of children overall receiving a prescription. The only exception to this was that antihypertensives remained fairly constant, 6.9% (95% CI, 3.7 – 11.3) for < 1 years, 7.6% (95% CI, 5.3 – 10.4) for 1 – 4 years and 8.3% (95% CI, 4.2 – 14.1) for 5 – 9 years (Table 2, Fig. 2).

*Mean number of prescriptions per year*: the mean number of prescriptions per 100 children per year were highest for children with sCHD <1 years of age at 91.1 (95% CI, 51.8 - 130.5). In all age groups and categories the highest mean number of prescriptions were found for children with sCHD (Table 3).

**Discussion**

In the present study we find that i) prescription of CVM was associated with severity of CA, as the highest proportion of children receiving a CVM prescription in their first 10 years of life are children with sCHD, ii) proportionally more children receive prescriptions of CVM in their first year of life for all subgroups of anomalies, and iii) diuretics and antihypertensives are the most frequently used CVM.

The most prevalent severe congenital heart defects include; atrioventricular septal defect (AVSD), tetralogy of Fallot (TOF), transposition of the great arteries (TGA), double outlet right ventricle (DORV) and hypoplastic left heart syndrome (HLHS)19. Although the surgical strategy differs between defects (i.e. complete operative correction in one procedure for AVSD versus staged repair in HLHS), complete surgical correction is recommended in all cases within the first year of life20-24. Albeit surgical repair is not without risk, results have improved substantially over the past 50 years and survival into adulthood is expected for almost all children born with CHD25. In the light of this; it seems reasonable that most CVM is given within the first year of life, either as a bridge to corrective surgery or in the post-operative period. In the present study, we do not have access to information regarding the indication for which the CVM was prescribed. However, the observation that the most frequently prescribed CVM in the first year of life is diuretics, appears to fit the picture of medication used as either a bridge to corrective surgery or use in the immediate post-operative phase. The use of diuretics in children ages 1-4 years and 5-9 years could reflect either chronic heart failure treatment or shorter courses given in relation to re-operations. Antihypertensives, including angiotensin converting enzyme inhibitors (ACEi), are widely used in paediatric heart failure 26, despite lack of proven clinical efficacy27. The prescription of antihypertensives to children with sCHD might therefore well reflect a subset of children receiving ACEi treatment for chronic heart failure.

Because the subset of sCHD is included in the CHD group, it is not possible to accurately address how much of the CVM prescription in CHD is driven by the subset of sCHD. It is, however, possible to look at children with a diagnosis of VSD that had no sCHD diagnosis. This group will include both isolated VSD, but also those occurring in combination with other minor cardiac anomalies such as an ASD, PDA or pulmonary valve stenosis. The reported incidence of VSD in neonates is highly dependent on the quality/availability of imaging, as a large subset of muscular VSD will close spontaneously without ever causing symptoms28. Dependent on detection rates of asymptomatic cases, somewhere between 5 – 10 % of isolated VSD cases will require surgical intervention29. In our data, we find that 7.4% (95% CI, 3.5 – 13.2) of the children in the VSD subgroup will receive a CVM prescription in their first year of life. It seems reasonable to assume, that this is the subset that will require surgery.

Arrhythmias in CHD can either be caused by i) the defect itself (i.e. sinoatrial Wenckeback in TGA), ii) an immediate post-operative complication (i.e. junctional ectopic tachycardia) or iii) arise as a late post-operative complication (most frequently atrial arrhythmias)30. In Europe, the majority of centres used either flecanide (VWC1) or atenolol (VWC2) for the management of supraventricular arrhythmias31. In our population, VWC1 medication was rarely used whereas VWC2 medication was more frequently prescribed. Although digoxin was recommended in the EHRA /AEPC-Arrhythmia

Working Group joint consensus statement30, when surveyed in the same year no centres in Europe reported using it for paediatric arrythmias31. As can been seen from Fig. 2; VWC5 was used in both Emilia Romagna (Italy) and Valencian Region (Spain), this most likely reflects digoxin prescription for supraventricular arrhythmias. Very few prescriptions for VW3 (i.e. amiodarone) were found in the present study. Guidelines suggest adding a VW3 class medication if treatment with a VW1 or VW2 does not achieve rhythm control. The low prescription rate of VW3 class medication might well reflect a tendency towards performing catheter ablation in patients where achieving rhythm control proves challenging31, rather than adding a second medication.

The main strength of this study is the population-based setting covering all children and not only those referred to tertiary hospitals for treatment26 31. Information is available on over 1.7 million children with potential to be linked from six European regions, in five countries covering both Northern and Southern Europe. In addition, the EUROCAT registries have a high level of case ascertainment and use standardized definitions and coding of CA to ensure consistency across Europe. The use of reference children for comparison enables interpretation of the results for children with CAs in the context of results for unaffected children. A limitation of this study is the lack of information about hospital prescribed medication. As a consequence, the exposure to CVM will be underestimated in this study. This will potentially have a bigger impact on children with more severe types of CHD as they are more likely to have a hospital admission. A second limitation is that not all children could be linked to the prescription databases due to, for example, invalid identification numbers. In tree regions we were able to link 100% of children, but in the tree other regions we were unable to link 5-14% of children. A third limitation is that the data from Wales are based on prescription by the general practitioner, rather than on pharmacy dispensed medication, this may overestimate the true amount due to medications being prescribed but never collected. We had intended to analyse data to see if there was a change in prescription rates over time in the three age groups. However, as some centres did not include data before 2008 or 2010, hence too few children were available in the older age categories. A recent study from Denmark and Norway found that prescription of CVM (measured as Defined Daily Doses) to children doubled during the study period from 1999 to 20167. Information on DDD was not extracted from the prescription databases for this study, because the use of DDD in studies on children is problematic. The dose for children is always calculated individually, at the time of prescribing, based on the actual weight or body surface area of the child. The hospital databases only have the weight of the child at birth and even with the actual weight at time of dispensation the comparisons of prescribed dose for children would be too uncertain. We therefore looked at individual prescription, which in our opinion, provides a better reflection of the medication burden. Another way to attempt to quantify the burden of medication is to look at the mean number of prescriptions which for instance for children with sCHD <1 years of age is 91 prescriptions per 100 children. Although this gives an indication of the burden it is not possible to directly infer the length of treatment from this number. How long a given prescriptions is used will depend both on the prescribed package size and the weight (and height) of the child, information which is not available in the databases.

In conclusion, we show that a large proportion of children with sCHD receive more CVM through their first 10 years of life. For all children with CHD, sCHD or VSD without sCHD the largest proportions of children receiving a CVM prescription are found in their first year of life, and then declined with advancing age. For children without CA the proportion of prescribed CVM is very low. The most frequently prescribed medications are diuretics and antihypertensives.

The burden of disease for children with CHD and sCHD includes the need for daily medications, but also other important aspects of the disease burden such as hospitalizations, length of stay and number of surgeries should be studied.

**Competing interests**

None declared.

**Funding**

This study has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 733001. The funding source had no role/influence on the design of the study, data collection, analysis or interpretation.

The views presented here are those of the authors only, and the European Commission is not responsible for any use that may be made of the information presented here.

**Data Availability Statement**

No additional data are available.

**Contributorship statement**

Mads Damkjær: wrote first draft of the paper and revised the paper after feedback

Stine Kjaer Urhoj: Extraction and analysis of local registry data. Gave continuous input in the process of drafting the paper.

Joachim Tan: Extraction and analysis of local registry data. Gave continuous input in the process of drafting the paper.

Gillian Briggs: Extraction and analysis of local registry data. Gave continuous input in the process of drafting the paper.

Maria Loane: Extraction and analysis of local registry data. Part of steering group and helped design of the study. Gave continuous input in the process of drafting the paper.

Joanne Given: Extraction and analysis of local registry data. Gave continuous input in the process of drafting the paper.

Laia Barrachina-Bonet: Extraction and analysis of local registry data. Gave continuous input in the process of drafting the paper.

Clara Cavero-Carbonell: Extraction and analysis of local registry data. Gave continuous input in the process of drafting the paper.

Alessio Coi: Extraction and analysis of local registry data. Gave continuous input in the process of drafting the paper.

Amanda J Neville: Extraction and analysis of local registry data. Gave continuous input in the process of drafting the paper.

Anna Heino: Extraction and analysis of local registry data. Gave continuous input in the process of drafting the paper.

Sonja Kiuru-Kuhlefelt: Extraction and analysis of local registry data. Gave continuous input in the process of drafting the paper.

Sue Jordan: Extraction and analysis of local registry data. Gave continuous input in the process of drafting the paper.

Ieuan Scanlon: Extraction and analysis of local registry data. Gave continuous input in the process of drafting the paper.

Anna Pierini: Extraction and analysis of local registry data. Gave continuous input in the process of drafting the paper.

Aurora Puccini: Extraction and analysis of local registry data. Gave continuous input in the process of drafting the paper.

Ester Garne: Extraction and analysis of local registry data. Part of steering group who designed the study. Gave continuous input in the process of drafting the paper.

Joan K Morris: Extraction and analysis of local registry data and meta-analysis of pooled data from each individual registry. Help revised paper. Part of steering group who designed the study.

**References**

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380(9859):2095-128. doi: 10.1016/s0140-6736(12)61728-0 [published Online First: 2012/12/19]

2. Zylbersztejn A, Gilbert R, Hjern A, et al. Child mortality in England compared with Sweden: a birth cohort study. *Lancet* 2018;391(10134):2008-18. doi: 10.1016/s0140-6736(18)30670-6 [published Online First: 2018/05/08]

3. Glinianaia SV, Morris JK, Best KE, et al. Long-term survival of children born with congenital anomalies: A systematic review and meta-analysis of population-based studies. *PLoS Med* 2020;17(9):e1003356. doi: 10.1371/journal.pmed.1003356 [published Online First: 2020/09/29]

4. Uzark K, Jones K, Slusher J, et al. Quality of life in children with heart disease as perceived by children and parents. *Pediatrics* 2008;121(5):e1060-7. doi: 10.1542/peds.2006-3778 [published Online First: 2008/05/03]

5. Abassi H, Huguet H, Picot MC, et al. Health-related quality of life in children with congenital heart disease aged 5 to 7 years: a multicentre controlled cross-sectional study. *Health Qual Life Outcomes* 2020;18(1):366. doi: 10.1186/s12955-020-01615-6 [published Online First: 2020/11/14]

6. Pedersen TA, Røpcke DM, Hjortdal VE. Functional health status late after surgical correction of aortic coarctation. *Congenit Heart Dis* 2011;6(6):566-72. doi: 10.1111/j.1747-0803.2011.00595.x [published Online First: 2011/11/29]

7. Poulsen CB, Damkjær M. Trends in prescription of cardiovascular drugs to children in relation to prevalence of CHD from 1999 to 2016. *Cardiol Young* 2018;28(9):1136-41. doi: 10.1017/s1047951118000951 [published Online First: 2018/07/12]

8. Schranz D, Voelkel NF. "Nihilism" of chronic heart failure therapy in children and why effective therapy is withheld. *Eur J Pediatr* 2016;175(4):445-55. doi: 10.1007/s00431-016-2700-3 [published Online First: 2016/02/21]

9. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease: The Task Force for the management of adult congenital heart disease of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Adult Congenital Heart Disease (ISACHD). *European Heart Journal* 2020;42(6):563-645. doi: 10.1093/eurheartj/ehaa554

10. [Available from: <https://www.eurolinkcat.eu/eurolinkcat> accessed 9th of April 2021.

11. Kinsner-Ovaskainen A, Lanzoni M, Garne E, et al. A sustainable solution for the activities of the European network for surveillance of congenital anomalies: EUROCAT as part of the EU Platform on Rare Diseases Registration. *European Journal of Medical Genetics* 2018;61(9):513-17. doi: 10.1016/j.ejmg.2018.03.008

12. Tucker FD, Morris JK, Committee JRCM, et al. EUROCAT: an update on its functions and activities. *J Community Genet* 2018;9(4):407-10. doi: 10.1007/s12687-018-0367-3 [published Online First: 2018/05/07]

13. Morris JK, Garne E, Loane M, et al. EUROlinkCAT protocol for a European population-based data linkage study investigating the survival, morbidity and education of children with congenital anomalies. *BMJ Open* 2021;11(6):e047859. doi: 10.1136/bmjopen-2020-047859 [published Online First: 2021/06/30]

14. EUROCAT. [Available from: <https://eu-rd-platform.jrc.ec.europa.eu/eurocat/eurocat-data/prevalence/guide_en#inline-nav-4>.

15. EUROCAT. Minor Anomalies and other conditions for Exclusion [Available from: <https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/JRC-EUROCAT-Section-3.2-23-9-2020.pdf> accessed May 25th 2021.

16. Dolk H, Loane M, Garne E, et al. Congenital heart defects in Europe: prevalence and perinatal mortality, 2000 to 2005. *Circulation* 2011;123(8):841-9. doi: 10.1161/CIRCULATIONAHA.110.958405 [published Online First: 2011/02/16]

17. Fuster V, Rydén LE, Cannom DS, et al. [ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--excutive summary]. *Rev Port Cardiol* 2007;26(4):383-446. [published Online First: 2007/08/19]

18. EUROlinkCAT. Parents area 2017 [Available from: [https://www.eurolinkcat.eu/\*parentsarea\*](https://www.eurolinkcat.eu/*parentsarea*).

19. Boyd PA, Haeusler M, Barisic I, et al. Paper 1: The EUROCAT network--organization and processes. *Birth Defects Res A Clin Mol Teratol* 2011;91 Suppl 1:S2-15. doi: 10.1002/bdra.20780 [published Online First: 2011/03/09]

20. Kobayashi M, Takahashi Y, Ando M. Ideal timing of surgical repair of isolated complete atrioventricular septal defect. *Interact Cardiovasc Thorac Surg* 2007;6(1):24-6. doi: 10.1510/icvts.2006.134288 [published Online First: 2007/08/03]

21. Mahle WT, Martinez R, Silverman N, et al. Anatomy, echocardiography, and surgical approach to double outlet right ventricle. *Cardiol Young* 2008;18 Suppl 3:39-51. doi: 10.1017/s1047951108003284 [published Online First: 2009/01/15]

22. Van Arsdell GS, Maharaj GS, Tom J, et al. What is the optimal age for repair of tetralogy of Fallot? *Circulation* 2000;102(19 Suppl 3):Iii123-9. doi: 10.1161/01.cir.102.suppl\_3.iii-123 [published Online First: 2000/11/18]

23. Meza JM, Hickey EJ, Blackstone EH, et al. The Optimal Timing of Stage 2 Palliation for Hypoplastic Left Heart Syndrome: An Analysis of the Pediatric Heart Network Single Ventricle Reconstruction Trial Public Data Set. *Circulation* 2017;136(18):1737-48. doi: 10.1161/circulationaha.117.028481 [published Online First: 2017/07/09]

24. Anderson BR, Ciarleglio AJ, Hayes DA, et al. Earlier arterial switch operation improves outcomes and reduces costs for neonates with transposition of the great arteries. *J Am Coll Cardiol* 2014;63(5):481-7. doi: 10.1016/j.jacc.2013.08.1645 [published Online First: 2013/11/05]

25. Holst KA, Said SM, Nelson TJ, et al. Current Interventional and Surgical Management of Congenital Heart Disease: Specific Focus on Valvular Disease and Cardiac Arrhythmias. *Circ Res* 2017;120(6):1027-44. doi: 10.1161/circresaha.117.309186 [published Online First: 2017/03/18]

26. Moffett BS, Price JF. National prescribing trends for heart failure medications in children. *Congenit Heart Dis* 2015;10(1):78-85. doi: 10.1111/chd.12183

27. Kantor PF, Lougheed J, Dancea A, et al. Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines. *Can J Cardiol* 2013;29(12):1535-52. doi: 10.1016/j.cjca.2013.08.008 [published Online First: 2013/11/26]

28. van der Linde D, Konings EE, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. *J Am Coll Cardiol* 2011;58(21):2241-7. doi: 10.1016/j.jacc.2011.08.025

29. Jortveit J, Leirgul E, Eskedal L, et al. Mortality and complications in 3495 children with isolated ventricular septal defects. *Arch Dis Child* 2016;101(9):808-13. doi: 10.1136/archdischild-2015-310154 [published Online First: 2016/04/20]

30. Brugada J, Blom N, Sarquella-Brugada G, et al. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. *Europace* 2013;15(9):1337-82. doi: 10.1093/europace/eut082 [published Online First: 2013/07/16]

31. Hernández-Madrid A, Hocini M, Chen J, et al. How are arrhythmias managed in the paediatric population in Europe? Results of the European Heart Rhythm survey. *Europace* 2014;16(12):1852-6. doi: 10.1093/europace/euu313 [published Online First: 2014/11/25]

**Legends**:

**Fig 1**: Percentage of children in each category receiving at least one prescription for any cardiovascular medication (CVM). Age in years above each panel. Data from six European Regions in the 15 year period from 2000 - 2014. Abbreviations; CA, congenital anomaly; CHD, Congenital Heart Defect; sCHD, Severe Congenital Heart Defect. Please note children with more than one major anomaly may be included in more than one congenital anomaly subgroup (i.e. sCHD is included in both CHD and CA).

**Fig 2**: Percentage of children with Severe Congenital Heart Defect (sCHD) receiving at least one prescription of six different pharmacological classes of CVM. Data from six European Regions from 2000-2014. Abbreviations; VW1, Vaughn Williams class 1; VW2, Vaughn Williams class 2; VW3, Vaughn Williams class 3; VW5, Vaughn Williams class 5.

**Table 1**: Overview of the prescription databases from which data were extracted for the study. Abbreviations; CA, Congenital Anomaly; CHD, Congenital Heart Defect; sCHD, Severe Congenital Heart Defect; VSD, Ventricular Septal Defect.

**Table 2**: Percentage of children (95% CI) with any prescription according to age, anomaly and type of prescription. Abbreviations; CA, Congenital Anomaly; CHD, Congenital Heart Defect; sCHD, Severe Congenital Heart Defect; VSD, Ventricular Septal Defects; VW1, Vaughn Williams class 1; VW2, Vaughn Williams class 2; VW3, Vaughn Williams class 3; VW5, Vaughn Williams class 5. Please note that children with more than one major anomaly may be included in more than one congenital anomaly subgroup.

† Estimate for 5-9 years of age are based on only the three registries from Denmark, Finland and Wales

**Table 3**: Mean number of prescriptions per 100 children per yearand the 95% confidence intervals (CI). Blank cells reflect too small numbers to report. Abbreviations; CA, Congenital Anomaly; CHD, Congenital Heart Defect; sCHD, Severe Congenital Heart Defect; VSD, Ventricular Septal Defects; VW1, Vaughn Williams class 1; VW2, Vaughn Williams class 2; VW3, Vaughn Williams class 3; VW5, Vaughn Williams class 5. Please note that children with more than one major anomaly may be included in more than one congenital anomaly subgroup.

**Box 1**: Comparison of the Vaughn Williams Classification (VWC) and the WHO based Anatomical Therapeutical Classification (ATC).

# Table 1

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  | **Number of Children** | | | | |
|  | **Name of prescription database** | **Coverage** | **First Year of birth** | **Source of prescriptions** | **Reference population** | | **Any CA (includes CHD)** | **CHD (includes sCHD)** | **sCHD** | **VSD**  **without sCHD** |
| **Denmark: Funen** | The Danish National Prescription Registry | All of Denmark | 2000 | Dispensed by pharmacy | 72,355 | | 1,815 | 535 | 115 | 325 |
| **Finland** | KELA Register on reimbursed medication (Social Insurance Institution) | All of Finland | 2000 | Dispensed by pharmacy | 756,148 | | 33,174 | 12,135 | 1,763 | 8,533 |
| **Italy: Emilia Romagna** | AFT “Pharmaceutical territorial assistance” | 4,200,000 | 2008 | Dispensed by pharmacy | 250,832 | | 5,521 | 1534 | 379 | 940 |
| **Italy: Tuscany** | AFT “Pharmaceutical territorial assistance”, FED “Pharmaceutical hospital prescribing”. Prescription database only includes medications reimbursed by the national (or regional) health service | 3,700,000 | 2008 | Dispensed by pharmacy | 16,844 | | 3,057 | 1,095 | 213 | 737 |
| **Spain: Valencian Region** | Regional prescription and dispensing database (GAIA) | 5 million inhabitants | 2010 | Dispensed by pharmacy | 223,760 | | 4,308 | 1,380 | 267 | 695 |
| **UK: Wales** | Secure Anonymised Information linkage (SAIL) | ~70% of General Practitioner (GP) practices in Wales | 2000 | Prescribed by GP | 405,555 | | 13,165 | 3,000 | 655 | 1,500 |
| **Total number of children included** | | - |  | - | 1,725,496 | | 61,038 | 19,678 | 3,392 | 12,728 |

# Table 2

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Medication** | | | | | | |
| **Anomaly** | **Age group (years)** | **Any Cardiac Medication**  **% (95% CI)** | **Diuretics**  **% (95% CI)** | **Antihyper-**  **tensives**  **% (95% CI)** | **VWC1**  **% (95% CI)** | **VWC2**  **% (95% CI)** | **VWC3**  **% (95% CI)** | **VWC5**  **% (95% CI)** |
| **Reference** | <1 | 0.1 (0.0-0.1) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) |
| 1-4 | 0.1 (0.1-0.1) | 0.0 (0.0-0.0) | 0.0 (0.0-0.1) | 0.0 (0.0-0.0) | 0.0 (0.0-0.1) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) |
| 5-9† | 0.2 (0.1-0.4) | 0.0 (0.0-0.0) | 0.0 (0.0-0.1) | 0.0 (0.0-0.0) | 0.1 (0.0-0.4) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) |
| **Any CAs,** (includes CHD) | <1 | 5.9 (3.7-8.7) | 4.6 (2.5-7.7) | 1.0 (0.5-1.7) | 0.1 (0.0-0.2) | 0.7 (0.5-1.0) | 0.0 (0.0-0.1) | 0.4 (0.1-1.1) |
| 1-4 | 3.1 (2.8-3.4) | 2.0 (1.7-2.4) | 1.1 (0.8-1.4) | 0.1 (0.0-0.1) | 0.6 (0.5-0.8) | 0.0 (0.0-0.1) | 0.2 (0.1-0.3) |
| 5-9† | 2.3 (1.9-2.7) | 0.9 (0.8-1.1) | 1.2 (1.0-1.5) | 0.0 (0.0-0.1) | 0.7 (0.4-1.2) | 0.0 (0.0-0.1) | 0.0 (0.0-0.3) |
| **CHD**  (includes sCHD) | <1 | 13.3 (6.7-22.0) | 10.8 (4.7-19.8) | 2.0 (0.8-4.0) | 0.1 (0.0-0.5) | 1.5 (0.8-2.7) | 0.1 (0.0-0.2) | 1.0 (0.3-2.7) |
| 1-4 | 5.9 (4.4-7.6) | 4.1 (2.9-5.7) | 1.9 (1.1-3.0) | 0.1 (0.0-0.4) | 1.2 (0.9-1.5) | 0.1 (0.0-0.1) | 0.4 (0.1-0.9) |
| 5-9† | 3.7 (2.6-5.1) | 1.9 (1.4-2.7) | 1.7 (0.7-3.5) | 0.1 (0.0-0.2) | 1.3 (0.9-1.8) | 0.0 (0.0-0.1) | 0.1 (0.0-0.7) |
| **sCHD** | <1 | 42.9 (26.3-58.5) | 36.4 (18.6-54.5) | 6.9 (3.7-11.3) | 0.3 (0.0-1.2) | 5.5 (2.9-9.2) | 0.2 (0.1-0.6) | 3.2 (1.1-7.0) |
| 1-4 | 18.8 (14.8-23.1) | 14.1 (10.8-17.8) | 7.6 (5.3-10.4) | 0.2 (0.0-0.6) | 3.3 (2.1-5.0) | 0.2 (0.1-0.4) | 1.3 (0.7-2.2) |
| 5-9† | 15.8 (12.0-20.1) | 8.5 (7.1-10.1) | 8.3 (4.2-14.1) | 0.2 (0.0-0.7) | 4.5 (3.4-5.8) | 0.1 (0.0-0.4) | 0.3 (0.0-1.8) |
| **VSD**, excluding severe CHD | <1 | 7.4 (3.5-13.2) | 6.3 (2.7-11.9) | 0.9 (0.3-2.4) | 0.1 (0.0-0.3) | 0.5 (0.3-0.7) | 0.1 (0.0-0.1) | 0.5 (0.1-1.9) |
| 1-4 | 2.6 (1.7-3.9) | 1.9 (1.0-3.2) | 0.4 (0.1-1.0) | 0.1 (0.0-0.1) | 0.4 (0.3-0.6) | 0.1 (0.0-0.1) | 0.2 (0.0-0.7) |
| 5-9† | 0.9 (0.7-1.2) | 0.3 (0.2-0.4) | 0.2 (0.1-0.5) | 0.0 (0.0-0.1) | 0.4 (0.1-1.1) | 0.0 (0.0-0.1) | 0.0 (0.0-0.1) |

# Table 3

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Medication** | | | | | | |
| **Anomaly** | **Age group (years)** | **Any Cardiac Medication**  **n (95% CI)** | **Diuretics**  **n (95% CI)** | **Antihyper-**  **tensives**  **% (95% CI)** | **VWC1**  **n (95% CI)** | **VWC2**  **n (95% CI)** | **VWC3**  **n (95% CI)** | **VWC5**  **n (95% CI)** |
| **Reference** | <1 | 25.3 (12.7-38.0) | 16.1 (7.4-24.7) | 4.0 (2.1-5.9) | 0.4 (0.0-0.7) | 3.6 (1.8-5.3) | 0.0 (0.0-0.0) | 1.5 (0.7-2.2) |
| 1-4 | 9.3 (7.8-10.9) | 3.5 (2.9-4.1) | 3.1 (2.5-3.8) | 0.1 (0.0-0.2) | 1.3 (0.9-1.6) | 0.0 (0.0-0.0) | 0.3 (0.2-0.5) |
| 5-9† | 7.9 (6.7-9.1) | 1.3 (1.0-1.6) | 4.2 (3.4-4.9) | 0.0 (0.0-0.0) | 1.3 (0.9-1.8) | 0.0 (0.0-0.1) | 0.6 (0.3-0.9) |
| **Any CAs,** (includes CHD) | <1 | 0.2 (0.1-0.3) | 0.0 (0.0-0.1) | 0.0 (0.0-0.0) | 0.0 (0.0-0.1) | 0.1 (0.0-0.1) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) |
| 1-4 | 0.1 (0.1-0.2) | 0.0 (0.0-0.0) | 0.0 (0.0-0.1) | 0.0 (0.0-0.0) | 0.1 (0.0-0.1) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) |
| 5-9† | 0.2 (0.2-0.3) | 0.0 (0.0-0.0) | 0.1 (0.1-0.1) | 0.0 (0.0-0.0) | 0.1 (0.1-0.2) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) |
| **CHD**  (includes sCHD) | <1 | 53.3 (26.7-79.8) | 35.1 (16.2-54.1) | 7.8 (3.6-12.0) | 1.2 (0.2-2.6) | 7.9 (3.5-12.3) | 0.1 (0.0-0.3) | 3.4 (1.6-5.3) |
| 1-4 | 15.8 (12.9-18.7) | 5.9 (4.5-7.3) | 4.6 (3.6-5.7) | 0.3 (0.1-0.5) | 2.4 (1.8-3.0) | 0.0 (0.0-0.0) | 0.8 (0.5-1.1) |
| 5-9† | 13.3 (10.8-15.8) | 2.6 (2.0-3.3) | 6.6 (5.1-8.1) | 0.0 (0.0-0.1) | 2.2 (1.7-2.7) | 0.1 (0.0-0.2) | 2.3 (1.2-3.5) |
| **sCHD** | <1 | 91.1 (51.8-130.5) | 62.5 (32.9-92.1) | 18.3 (9.2-27.4) | 4.7 (1.0-8.4) | 21.8 (9.9-33.7) | 0.7 (0.1-1.3) | 7.2 (3.3-11.2) |
| 1-4 | 43.9 (34.0-53.8) | 20.7 (15.1-26.2) | 17.5 (13.1-22.0) | 0.5 (0.0-0.9) | 5.8 (3.9-7.8) | 0.1 (0.0-0.2) | 4.1 (2.4-5.8) |
| 5-9† | 49.0 (38.3-59.7) | 12.7 (9.8-15.5) | 28.0 (20.6-35.4) | 0.2 (0.00-0.4) | 6.9 (5.6-8.3) | 0.6 (0.0-1.4) | 5.6 (2.0-9.2) |
| **VSD**, excluding severe CHD | <1 | 24.4 (11.9-36.9) | 19.0 (8.2-29.9) | 3.9 (1.1-6.6) | 0.2 (0.0-0.5) | 1.0 (0.4-1.7) | 0.5 (0.0-1.6) | 0.9 (0.1-1.7) |
| 1-4 | 2.9 (1.8-3.9) | 1.5 (0.9-2.1) | 0.4 (0.2-0.7) | 0.1 (0.0-0.4) | 0.6 (0.3-0.8) | 0.2 (0.0-0.5) | 0.2 (0.0-0.5) |
| 5-9† | 1.4 (0.9-1.8) | 0.1 (0.0-0.2) | 0.4 (0.2-0.6) | - | 1.1 (0.8-1.4) | - | 1.3 (0.0-3.1) |

# Box 1

|  |  |  |  |
| --- | --- | --- | --- |
| **Vaugh Williams** | **ATC codes** | **Examples** | **Mechanism of action** |
| Class I | C01BA  (Class Ia) C01BB  (Class Ib) C01BC  (Class Ic) | Procainamide  Lidocaine  Flecainide | Fast-sodium channel blockers |
| Class II | C07AA  (non-selective) C07AB  (selective) C07AG  (alpha and betablockers) | Propranolol  Atenolol  Carvedilol | Beta-blockers |
| Class III | C01BD (Class III) | Amiodarone | Potassium channel blockers |
| Class IV | C08C  C08D  C08E C08G | Nifedipine | Calcium channel blockers |
| Class V | C01A  C01EB | Digoxin  Adenosine | Other mechanism of action |